peptide hormone comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-01-25. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
Coller (1966), father of Abciximab, vice president and physician-in-chief at Rockefeller University Peter Gray (1966), psychologist; professor at Boston College Brian Weiss (1966), psychiatrist noted for his research on reincarnation and past life regression Richard Axel (1967), winner of the Nobel Prize in Physiology or Medicine for studying the operations of the olfactory system Nai Phuan Ong (1967), professor of Physics at Princeton University Nick Scoville (1967), professor of astronomy at California Institute of Technology Robert Wald (1968), theoretical physicist at the University of Chicago Sidney R. Nagel (1969), University of Chicago physicist specializing in the complex physics of everyday materials Thomas B. Kornberg (1970), biochemist who was the first to purify and characterize DNA polymerase II and DNA polymerase III Harold J. Vinegar (1970), former chief scientist for physics of Shell plc, professor at Ben-Gurion University of the Negev Franklin G. Miller (1971), bioethicist at the National Institutes of Health Eric Rose (1971), cardiothoracic surgeon known for performing the first successful paediatric heart transplant; former president of the International Society for Heart and Lung Transplantation Paul S. Appelbaum (1972), psychiatrist credited with conceptualizing the idea of therapeutic misconception Steven M. Bellovin (1972), professor of computer science at Columbia University and chief technologist of Federal Trade Commission Rick L.
Sink test is a form of medical laboratory diagnostics healthcare fraud whereby clinical specimens are discarded, via a sink drain, and fabricated results are reported, without the clinical specimen actually being tested. In the United States, the prevalence of sink test laboratories in the 1980s led in part to regulation following the passage of Clinical Laboratory Improvement Amendments in 1988. While this illegal practice still occurs, it is rare within the highly regulated US lab market.
Initially, an enzyme known as a helicase acts on the molecule of DNA. DNA has an antiparallel, double helix structure composed of two, complementary polynucleotide strands, held together by hydrogen bonds between the base pairs. The helicase disrupts the hydrogen bonds causing a region of DNA – corresponding to a gene – to unwind, separating the two DNA strands and exposing a series of bases. Despite DNA being a double-stranded molecule, only one of the strands acts as a template for pre-mRNA synthesis; this strand is known as the template strand. The other DNA strand (which is complementary to the template strand) is known as the coding strand. Both DNA and RNA have intrinsic directionality, meaning there are two distinct ends of the molecule. This property of directionality is due to the asymmetrical underlying nucleotide subunits, with a phosphate group on one side of the pentose sugar and a base on the other. The five carbons in the pentose sugar are numbered from 1' (where ' means prime) to 5'. Therefore, the phosphodiester bonds connecting the nucleotides are formed by joining the hydroxyl group on the 3' carbon of one nucleotide to the phosphate group on the 5' carbon of another nucleotide. Hence, the coding strand of DNA runs in a 5' to 3' direction and the complementary, template DNA strand runs in the opposite direction from 3' to 5'.
Tyrannosaurus is the most widely known dinosaur in popular culture. Science writer Riley Black states, "In all of prehistory, there is no animal that commands our attention quite like Tyrannosaurus rex... Since the time this dinosaur was officially named in 1905, the enormous carnivore has stood as the ultimate dinosaur." Paleontologist David Hone notes the popularity of Tyrannosaurus models and skeletal displays in museums and writes that films like Jurassic Park and King Kong "would not have been the same without it." T. rex is the only dinosaur that is commonly known to the general public by its full scientific name (binomial name) and the scientific abbreviation T. rex has also come into wide usage.
Sources: en.wikipedia.org
Plutonium-238 (238Pu or Pu-238) is a radioactive isotope of plutonium that has a half-life of 87.7 years. Plutonium-238 is a very powerful alpha emitter; as alpha particles are easily blocked, this makes the plutonium-238 isotope suitable for usage in radioisotope thermoelectric generators (RTGs) and radioisotope heater units. The density of plutonium-238 at room temperature is about 19.8 g/cc. The material will generate about 0.57 watts per gram of 238Pu. The bare sphere critical mass of metallic plutonium-238 is not precisely known, but its calculated range is between 9.04 and 10.07 kg (19.9 and 22.2 lb).
==== Live material ==== Some live cell cultures can be freeze-dried, stored for an extended period, and then reconstituted into a live, functional state. An excipient, more specifically a cryoprotectant, may be required.
Pantothenic acid is a water-soluble vitamin, one of the B vitamins. It is synthesized from the amino acid β-alanine and pantoic acid (see biosynthesis and structure of coenzyme A figures). Unlike vitamin E or vitamin K, which occurs in several chemically related forms known as vitamers, pantothenic acid is only one chemical compound. It is a starting compound in the synthesis of coenzyme A (CoA), a cofactor for many enzyme processes.
Sources: en.wikipedia.org
Refers to any of the FDA procedures, such as compassionate use, parallel track, and treatment IND that distribute experimental drugs to participants who are failing on currently available treatments for their condition and also are unable to participate in ongoing clinical trials. (NLM) Expanded access trial
=== Twitter defamation case === In April 2022, Galloway's Twitter account was labelled "Russian state-affiliated media" by Twitter. In response Galloway tweeted: "I work for NO Russian media. I have 400,000 followers. I'm the leader of a British political party and spent nearly 30 years in the British parliament. If you do not remove this designation I will take legal action." Twitter users pointed out that Galloway's profile named the Russian state media outlets that he worked for. Galloway then removed these from his profile. He said Twitter had refused to explain the label, which he said was added to his account after he had stopped presenting on Russian television channels, which were closed by the British government in March 2022. Galloway sued Twitter for defamation in the High Court, Dublin. The suit also alleged that Twitter had unlawfully processed his personal data by labelling and censoring his account. In October 2024, the High Court in Dublin ordered Twitter to pay Galloway's legal costs. It also ordered both parties to "submit sworn affidavits attesting to the truth of their claims" by 30 January 2025.
Mealworms (Tenebrio molitor) as larvae Lesser mealworms (Alphitobius diaperinus) as larvae, mostly marketed under the term buffalo worms. House cricket (Acheta domesticus) Tropical house cricket (Gryllodes sigillatus) European migratory locust (Locusta migratoria) Black soldier fly (Hermetia illucens) Housefly (Musca domestica) Cochineal (Dactylopius coccus) is collected to produce carmine, a red dye used for textiles and food. It was largely substituted with synthetic dyes like alizarin. Fears over the safety of artificial food additives renewed the popularity of cochineal dyes, and the increased demand has made cultivation of the insect profitable again, with Peru being the largest producer, followed by Mexico, Chile, Argentina and the Canary Islands.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.